๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Comparison of a clock drawing test in elderly schizophrenia and Alzheimer's disease patients: a preliminary study

โœ Scribed by Jeremia Heinik; Debbi Lahav; Dov Drummer; Zippi Vainer-Benaiah; Ruth Lin


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
62 KB
Volume
15
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


THE CLOCK DRAWING TEST FOR DEMENTIA OF T
โœ HENRY BRODATY; CRESSIDA M. MOORE ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 143 KB ๐Ÿ‘ 1 views

## Objectives: To examine the reliability and validity of the clock drawing test when used as a cognitive screening instrument for mild to moderate dementia, and to compare different scoring mechanisms. ## Design: Retrospective analysis of clock drawing performance using three published scoring m

A comparison of sleep profiles in patien
โœ J. B Grace; M. P Walker; I. G McKeith ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 60 KB ๐Ÿ‘ 2 views

Introduction[ Sleep disturbances are common in healthy old age and in dementia syndromes[ Polysomnography has demonstrated typical changes in both Alzheimer|s disease "AD# and dementia with Lewy bodies "DLB# with AD being characterised by sundowning and sleep apnoea and DLB patients showing more dis

The 3111T/C polymorphism of the CLOCK ge
โœ Alfonso Tortorella; Palmiero Monteleone; Vassilis Martiadis; Francesco Perris; M ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 59 KB ๐Ÿ‘ 2 views

## Abstract Feeding is subjected to circadian regulation; therefore, changes in the components of the endogenous oscillator regulating circadian rhythms may be involved in disordered rhythmicity of eating behavior as it occurs in anorexia nervosa (AN) and bulimia nervosa (BN). We investigated wheth

A multicentre, randomized, double-blind,
โœ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 139 KB ๐Ÿ‘ 2 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre